Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...

London: GSK plc has announced that the US Food and Drug Administration (FDA) has accepted for review an application to extend ...

The Food and Drug Administration on Wednesday approved Arexvy, the world's first respiratory syncytial virus (RSV) vaccine — a scientific breakthrough 60 years in the making.

GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in ...

Up to 10,000 deaths and 160,000 hospitalizations a year are caused by RSV in ... The FDA's decision follows wide majority votes in favor of the safety and efficacy of GSK's Arexvy vaccine at an ...

The US FDA approved an RSV vaccine called Arexvy. How effective is it, when will it be available, and who can take it? CNN Medical Analyst Dr. Leana Wen explains.

The Food and Drug Administration Wednesday approved Arexvy, the first vaccine against severe respiratory syncytial virus, more commonly known as RSV. Highly contagious, RSV causes infections of ...

The safety and immunogenicity of Arexvy in adults aged 18 to 49 years at increased risk of RSV disease (n=395) was compared with adults aged 60 and older (n=417) in a phase 3b open-label trial ...

Health Canada has approved an RSV vaccine for adults over the age of 60 — something many doctors were "happy" to learn. The agency approved GSK’s Arexvy vaccine for the prevention of RSV ...